Drug­mak­ers do not ex­pect third-par­ty man­u­fac­tur­ers to in­crease their psy­che­del­ic ser­vices just yet, even af­ter Pres­i­dent Don­ald Trump is­sued an ex­ec­u­tive or­der de­signed to ex­pe­dite...

A WuXi Bi­o­log­ics fac­to­ry un­der con­struc­tion in Mass­a­chu­setts is slat­ed to be com­plet­ed in 2028 — a decade af­ter the com­pa­ny first an­nounced its plans...

Mer­ck KGaA has said it is shop­ping for deals. And on Thurs­day, the Ger­man con­glom­er­ate re­vealed it will make its largest ac­qui­si­tion in a decade...

The Trump ad­min­is­tra­tion is re­spond­ing to a drum­beat of calls from the biotech and phar­ma in­dus­tries to mod­ern­ize and ex­pe­dite clin­i­cal tri­als with a sweep­ing...

Amid Ger­many's on­go­ing re­view of its health­care spend­ing, the US gov­ern­ment has start­ed a trade in­ves­ti­ga­tion in­to the Eu­ro­pean coun­try's drug pric­ing sys­tem.

The in­ves­ti­ga­tion...

As com­pa­nies grap­ple with how to best com­pete with — or voice con­cerns over — Chi­na’s grow­ing biotech prowess, craft­ing a po­lit­i­cal strat­e­gy has be­come...

Plus, news about Ad­van­Cell and Ju­bi­lant.

🔴 FDA re­jects drug for nico­tine de­pen­dence: Achieve Life Sci­ences